Cargando…
Differences in sarcopenia prevalence between upper-body and lower-body based EWGSOP2 muscle strength criteria: the Tromsø study 2015–2016
BACKGROUND: The European Working Group on Sarcopenia in Older People (EWGSOP2) recommends grip strength and chair stand tests to be used as primary defining measures. It is unclear how either test affects prevalence estimates. METHODS: This cross-sectional study involved 3498 community-dwelling part...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654146/ https://www.ncbi.nlm.nih.gov/pubmed/33172391 http://dx.doi.org/10.1186/s12877-020-01860-w |
_version_ | 1783608013414727680 |
---|---|
author | Johansson, Jonas Strand, Bjørn Heine Morseth, Bente Hopstock, Laila Arnesdatter Grimsgaard, Sameline |
author_facet | Johansson, Jonas Strand, Bjørn Heine Morseth, Bente Hopstock, Laila Arnesdatter Grimsgaard, Sameline |
author_sort | Johansson, Jonas |
collection | PubMed |
description | BACKGROUND: The European Working Group on Sarcopenia in Older People (EWGSOP2) recommends grip strength and chair stand tests to be used as primary defining measures. It is unclear how either test affects prevalence estimates. METHODS: This cross-sectional study involved 3498 community-dwelling participants (40–84 years) from the 7th Tromsø Study survey (2015–2016). We used grip strength, five-repetition chair stands, four-meter Walk Speed Test, Timed-Up-and-Go (TUG) and Dual-Energy X-ray Absorptiometry measurements. Data were analyzed using multiple linear regression models and ROC-curves. RESULTS: Probable and confirmed sarcopenia prevalence was 1.3 and 4.4% based on grip strength and chair stands, respectively. There was very low agreement between grip strength and chair stand cut-offs (κ = 0.07), with only 4.3% of participants defined as having probable sarcopenia overlapping in the two criteria. Participants with grip strength-based sarcopenia had lower mean height, weight, waist circumference, and appendicular lean mass relative to body height (ALM(height)(2)) than non-sarcopenic participants (all p < 0.001), after adjusting for multiple covariates. Conversely, participants with chair stand-based sarcopenia had similar height, higher weight, waist circumference and body fat% compared to non-sarcopenic participants (all p < 0.05). Area-under-curves (AUCs) for TUG-time were significantly larger when using chair stand instead of grip strength cut-offs (0.86, 95% CI 0.84–0.89 vs. 0.75, 95% CI 0.69–0.83). CONCLUSIONS: Using chair stands instead of grip strength more than doubled probable sarcopenia prevalence across all ages. The two measures defined individuals of contradictory anthropometrics, body composition, and dissimilar physical function to have probable sarcopenia. Researchers should further evaluate the consequences of using different strength measures in the EWGSOP2 definition to classify sarcopenia. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12877-020-01860-w. |
format | Online Article Text |
id | pubmed-7654146 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-76541462020-11-10 Differences in sarcopenia prevalence between upper-body and lower-body based EWGSOP2 muscle strength criteria: the Tromsø study 2015–2016 Johansson, Jonas Strand, Bjørn Heine Morseth, Bente Hopstock, Laila Arnesdatter Grimsgaard, Sameline BMC Geriatr Research Article BACKGROUND: The European Working Group on Sarcopenia in Older People (EWGSOP2) recommends grip strength and chair stand tests to be used as primary defining measures. It is unclear how either test affects prevalence estimates. METHODS: This cross-sectional study involved 3498 community-dwelling participants (40–84 years) from the 7th Tromsø Study survey (2015–2016). We used grip strength, five-repetition chair stands, four-meter Walk Speed Test, Timed-Up-and-Go (TUG) and Dual-Energy X-ray Absorptiometry measurements. Data were analyzed using multiple linear regression models and ROC-curves. RESULTS: Probable and confirmed sarcopenia prevalence was 1.3 and 4.4% based on grip strength and chair stands, respectively. There was very low agreement between grip strength and chair stand cut-offs (κ = 0.07), with only 4.3% of participants defined as having probable sarcopenia overlapping in the two criteria. Participants with grip strength-based sarcopenia had lower mean height, weight, waist circumference, and appendicular lean mass relative to body height (ALM(height)(2)) than non-sarcopenic participants (all p < 0.001), after adjusting for multiple covariates. Conversely, participants with chair stand-based sarcopenia had similar height, higher weight, waist circumference and body fat% compared to non-sarcopenic participants (all p < 0.05). Area-under-curves (AUCs) for TUG-time were significantly larger when using chair stand instead of grip strength cut-offs (0.86, 95% CI 0.84–0.89 vs. 0.75, 95% CI 0.69–0.83). CONCLUSIONS: Using chair stands instead of grip strength more than doubled probable sarcopenia prevalence across all ages. The two measures defined individuals of contradictory anthropometrics, body composition, and dissimilar physical function to have probable sarcopenia. Researchers should further evaluate the consequences of using different strength measures in the EWGSOP2 definition to classify sarcopenia. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12877-020-01860-w. BioMed Central 2020-11-10 /pmc/articles/PMC7654146/ /pubmed/33172391 http://dx.doi.org/10.1186/s12877-020-01860-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Johansson, Jonas Strand, Bjørn Heine Morseth, Bente Hopstock, Laila Arnesdatter Grimsgaard, Sameline Differences in sarcopenia prevalence between upper-body and lower-body based EWGSOP2 muscle strength criteria: the Tromsø study 2015–2016 |
title | Differences in sarcopenia prevalence between upper-body and lower-body based EWGSOP2 muscle strength criteria: the Tromsø study 2015–2016 |
title_full | Differences in sarcopenia prevalence between upper-body and lower-body based EWGSOP2 muscle strength criteria: the Tromsø study 2015–2016 |
title_fullStr | Differences in sarcopenia prevalence between upper-body and lower-body based EWGSOP2 muscle strength criteria: the Tromsø study 2015–2016 |
title_full_unstemmed | Differences in sarcopenia prevalence between upper-body and lower-body based EWGSOP2 muscle strength criteria: the Tromsø study 2015–2016 |
title_short | Differences in sarcopenia prevalence between upper-body and lower-body based EWGSOP2 muscle strength criteria: the Tromsø study 2015–2016 |
title_sort | differences in sarcopenia prevalence between upper-body and lower-body based ewgsop2 muscle strength criteria: the tromsø study 2015–2016 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654146/ https://www.ncbi.nlm.nih.gov/pubmed/33172391 http://dx.doi.org/10.1186/s12877-020-01860-w |
work_keys_str_mv | AT johanssonjonas differencesinsarcopeniaprevalencebetweenupperbodyandlowerbodybasedewgsop2musclestrengthcriteriathetromsøstudy20152016 AT strandbjørnheine differencesinsarcopeniaprevalencebetweenupperbodyandlowerbodybasedewgsop2musclestrengthcriteriathetromsøstudy20152016 AT morsethbente differencesinsarcopeniaprevalencebetweenupperbodyandlowerbodybasedewgsop2musclestrengthcriteriathetromsøstudy20152016 AT hopstocklailaarnesdatter differencesinsarcopeniaprevalencebetweenupperbodyandlowerbodybasedewgsop2musclestrengthcriteriathetromsøstudy20152016 AT grimsgaardsameline differencesinsarcopeniaprevalencebetweenupperbodyandlowerbodybasedewgsop2musclestrengthcriteriathetromsøstudy20152016 |